President Donald Trump announced that reducing prescription drug costs will be a central focus ahead of the upcoming midterm elections. He described the initiative as a significant policy effort aimed at providing financial relief to Americans who face high medication expenses each year. According to Trump, making treatments more affordable has been a long-standing objective of his administration and remains a priority moving forward.
As part of the proposal, Trump stated that Pfizer has agreed to offer state Medicaid programs access to certain medications at “most-favored-nation” pricing levels. This model is designed to align U.S. prices more closely with some of the lowest rates available in other developed countries. Examples shared include reported price reductions for medications such as Eucrisa for dermatitis, Xeljanz for rheumatoid arthritis, and Zavzpret for migraine treatment, with varying levels of cost adjustments.
Trump indicated that this agreement represents an initial step in a broader strategy to address prescription drug pricing across the country. He noted that discussions with additional pharmaceutical companies are ongoing and suggested that further announcements could follow. The administration has presented the effort as part of a wider approach to restructuring how medications are priced in the United States compared to other nations.
The President also highlighted the potential economic impact of lower drug prices on households, stating that reduced costs could ease pressure on family budgets. He emphasized the goal of creating a balance between maintaining innovation within the pharmaceutical industry and expanding affordability for consumers. Supporters view the initiative as an effort to improve access to necessary treatments while sustaining a competitive healthcare market.